Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is spearheading a ...

New data from Eli Lilly (LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis and bowel ...

Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on ...

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Eli Lilly will submit orforglipron to be part of FDA’s new national priority voucher program, according to a new report. 1 ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

In its mission to enlighten others to the symptoms of obstructive sleep apnea (OSA), Eli Lilly is getting an assist from NBA ...